Extended-release oral minoxidil (VDPHL01) shows promising results for hair growth with improved safety, achieving significant hair count increases and minimal side effects compared to placebo. The treatment is designed to maintain effective concentrations while reducing side effects, making it a safer option for those who cannot tolerate standard minoxidil.
A dermatologist advised stopping finasteride after 3-6 months, but many users disagreed, stating it should be used indefinitely to maintain hair. Users recommended finding a new dermatologist due to the perceived misinformation.
A user shared their two-year progress using only topical finasteride for hair loss, recently adding keto shampoo, and plans for a hair transplant. They experienced regrowth and halted hair loss without using minoxidil due to side effects.
The conversation discusses potential hair loss treatments focusing on stimulating IGF-1 at the follicle level using growth-factor cocktails and engineered peptides, such as Acetyl Tetrapeptide-3, Copper Tripeptide-1, Oligopeptide-20, Thymosin-β4, and Palmitoyl Tetrapeptide-7. It suggests that device-assisted delivery methods like microneedling may enhance effectiveness.
TGF-B affects hair growth, both causing stem cell division and death depending on amounts. Amplifica's treatment injects Scube3 to increase TGF-B for hair growth.